vs
ADMA BIOLOGICS, INC.（ADMA）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
Purple Innovation, Inc.的季度营收约是ADMA BIOLOGICS, INC.的1.0倍（$140.7M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -2.3%，领先37.8%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 9.1%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $-7.8M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 8.3%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
ADMA vs PRPL — 直观对比
营收规模更大
PRPL
是对方的1.0倍
$139.2M
营收增速更快
ADMA
高出9.3%
9.1%
净利率更高
ADMA
高出37.8%
-2.3%
自由现金流更多
ADMA
多$42.4M
$-7.8M
两年增速更快
ADMA
近两年复合增速
8.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $140.7M |
| 净利润 | $49.4M | $-3.2M |
| 毛利率 | 63.8% | 41.9% |
| 营业利润率 | 45.1% | -1.6% |
| 净利率 | 35.5% | -2.3% |
| 营收同比 | 18.4% | 9.1% |
| 净利润同比 | -55.9% | 62.1% |
| 每股收益（稀释后） | $0.20 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAPRPL
| Q4 25 | $139.2M | $140.7M | ||
| Q3 25 | $134.2M | $118.8M | ||
| Q2 25 | $122.0M | $105.1M | ||
| Q1 25 | $114.8M | $104.2M | ||
| Q4 24 | $117.5M | $129.0M | ||
| Q3 24 | $119.8M | $118.6M | ||
| Q2 24 | $107.2M | $120.3M | ||
| Q1 24 | $81.9M | $120.0M |
净利润ADMAPRPL
| Q4 25 | $49.4M | $-3.2M | ||
| Q3 25 | $36.4M | $-11.7M | ||
| Q2 25 | $34.2M | $-17.3M | ||
| Q1 25 | $26.9M | $-19.1M | ||
| Q4 24 | $111.9M | $-8.5M | ||
| Q3 24 | $35.9M | $-39.2M | ||
| Q2 24 | $32.1M | $27.0K | ||
| Q1 24 | $17.8M | $-50.2M |
毛利率ADMAPRPL
| Q4 25 | 63.8% | 41.9% | ||
| Q3 25 | 56.3% | 42.8% | ||
| Q2 25 | 55.1% | 35.9% | ||
| Q1 25 | 53.2% | 39.4% | ||
| Q4 24 | 53.9% | 42.9% | ||
| Q3 24 | 49.8% | 29.7% | ||
| Q2 24 | 53.6% | 40.7% | ||
| Q1 24 | 47.8% | 34.8% |
营业利润率ADMAPRPL
| Q4 25 | 45.1% | -1.6% | ||
| Q3 25 | 38.0% | -10.2% | ||
| Q2 25 | 35.1% | -13.5% | ||
| Q1 25 | 30.4% | -13.9% | ||
| Q4 24 | 32.6% | -6.0% | ||
| Q3 24 | 33.1% | -39.5% | ||
| Q2 24 | 36.6% | -12.1% | ||
| Q1 24 | 26.7% | -19.3% |
净利率ADMAPRPL
| Q4 25 | 35.5% | -2.3% | ||
| Q3 25 | 27.1% | -9.9% | ||
| Q2 25 | 28.1% | -16.5% | ||
| Q1 25 | 23.4% | -18.4% | ||
| Q4 24 | 95.2% | -6.6% | ||
| Q3 24 | 30.0% | -33.1% | ||
| Q2 24 | 29.9% | 0.0% | ||
| Q1 24 | 21.7% | -41.8% |
每股收益（稀释后）ADMAPRPL
| Q4 25 | $0.20 | $0.03 | ||
| Q3 25 | $0.15 | $0.11 | ||
| Q2 25 | $0.14 | $0.16 | ||
| Q1 25 | $0.11 | $0.18 | ||
| Q4 24 | $0.45 | $0.08 | ||
| Q3 24 | $0.15 | $0.36 | ||
| Q2 24 | $0.13 | $0.00 | ||
| Q1 24 | $0.08 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $24.3M |
| 总债务越低越好 | $72.1M | $126.7M |
| 股东权益账面价值 | $477.3M | $-29.7M |
| 总资产 | $624.2M | $296.3M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAPRPL
| Q4 25 | $87.6M | $24.3M | ||
| Q3 25 | $61.4M | $32.4M | ||
| Q2 25 | $90.3M | $34.2M | ||
| Q1 25 | $71.6M | $21.6M | ||
| Q4 24 | $103.1M | $29.0M | ||
| Q3 24 | $86.7M | $23.4M | ||
| Q2 24 | $88.2M | $23.4M | ||
| Q1 24 | $45.3M | $34.5M |
总债务ADMAPRPL
| Q4 25 | $72.1M | $126.7M | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMAPRPL
| Q4 25 | $477.3M | $-29.7M | ||
| Q3 25 | $431.2M | $-26.9M | ||
| Q2 25 | $398.3M | $-15.6M | ||
| Q1 25 | $373.4M | $1.3M | ||
| Q4 24 | $349.0M | $20.2M | ||
| Q3 24 | $231.9M | $28.0M | ||
| Q2 24 | $188.3M | $66.4M | ||
| Q1 24 | $153.7M | $65.5M |
总资产ADMAPRPL
| Q4 25 | $624.2M | $296.3M | ||
| Q3 25 | $568.7M | $302.1M | ||
| Q2 25 | $558.4M | $303.8M | ||
| Q1 25 | $510.6M | $293.8M | ||
| Q4 24 | $488.7M | $307.8M | ||
| Q3 24 | $390.6M | $309.3M | ||
| Q2 24 | $376.4M | $362.1M | ||
| Q1 24 | $350.9M | $382.1M |
负债/权益比ADMAPRPL
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $-7.8M |
| 自由现金流率自由现金流/营收 | 24.8% | -5.5% |
| 资本支出强度资本支出/营收 | 0.8% | 1.4% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $-41.9M |
8季度趋势，按日历期对齐
经营现金流ADMAPRPL
| Q4 25 | $35.6M | $-5.8M | ||
| Q3 25 | $13.3M | $-968.0K | ||
| Q2 25 | $21.1M | $-4.0M | ||
| Q1 25 | $-19.7M | $-23.1M | ||
| Q4 24 | $50.2M | $6.8M | ||
| Q3 24 | $25.0M | $1.1M | ||
| Q2 24 | $45.6M | $-8.9M | ||
| Q1 24 | $-2.2M | $-16.8M |
自由现金流ADMAPRPL
| Q4 25 | $34.6M | $-7.8M | ||
| Q3 25 | $-1.1M | $-1.8M | ||
| Q2 25 | $18.7M | $-7.0M | ||
| Q1 25 | $-24.4M | $-25.3M | ||
| Q4 24 | $47.5M | $5.7M | ||
| Q3 24 | $24.0M | $101.0K | ||
| Q2 24 | $43.6M | $-11.0M | ||
| Q1 24 | $-4.6M | $-19.9M |
自由现金流率ADMAPRPL
| Q4 25 | 24.8% | -5.5% | ||
| Q3 25 | -0.8% | -1.5% | ||
| Q2 25 | 15.3% | -6.6% | ||
| Q1 25 | -21.2% | -24.3% | ||
| Q4 24 | 40.4% | 4.4% | ||
| Q3 24 | 20.0% | 0.1% | ||
| Q2 24 | 40.7% | -9.2% | ||
| Q1 24 | -5.6% | -16.5% |
资本支出强度ADMAPRPL
| Q4 25 | 0.8% | 1.4% | ||
| Q3 25 | 10.7% | 0.7% | ||
| Q2 25 | 2.0% | 2.8% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 2.3% | 0.8% | ||
| Q3 24 | 0.9% | 0.9% | ||
| Q2 24 | 1.9% | 1.7% | ||
| Q1 24 | 2.9% | 2.5% |
现金转化率ADMAPRPL
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | -330.22× | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
